Mifepristone Induces Growth Arrest, Caspase Activation, and Apoptosis of Estrogen Receptor-Expressing, Antiestrogen-Resistant Breast Cancer Cells

Caspases: Enemies Within

1998 • 6,923 citations

Tamoxifen for early breast cancer: an overview of the randomised trials

1998 • 4,082 citations

Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.

1992 • 2,906 citations

Caspase-3 Is Required for DNA Fragmentation and Morphological Changes Associated with Apoptosis

1998 • 1,927 citations

Ordering the Cytochrome c–initiated Caspase Cascade: Hierarchical Activation of Caspases-2, -3, -6, -7, -8, and -10 in a Caspase-9–dependent Manner

1999 • 1,927 citations

The Therapeutic Potential of Poly(ADP-Ribose) Polymerase Inhibitors

2002 • 1,352 citations

Induction of Apoptosis by Cancer Chemotherapy

2000 • 1,239 citations

Estrogen receptor interaction with estrogen response elements

2001 • 1,031 citations

Aromatase Inhibitors in Breast Cancer

2003 • 882 citations

Five Versus More Than Five Years of Tamoxifen Therapy for Breast Cancer Patients With Negative Lymph Nodes and Estrogen Receptor-Positive Tumors

1996 • 870 citations

Double-Blind, Randomized Trial Comparing the Efficacy and Tolerability of Fulvestrant Versus Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing on Prior Endocrine Therapy: Results of a North American Trial

2002 • 645 citations

Proteasome-dependent degradation of the human estrogen receptor

1999 • 573 citations

Elevated Levels of Epidermal Growth Factor Receptor/c-erbB2 Heterodimers Mediate an Autocrine Growth Regulatory Pathway in Tamoxifen-Resistant MCF-7 Cells

2003 • 523 citations

Estrogen-induced Activation of Cdk4 and Cdk2 during G1-S Phase Progression Is Accompanied by Increased Cyclin D1 Expression and Decreased Cyclin-dependent Kinase Inhibitor Association with Cyclin E-Cdk2

1997 • 438 citations

RU486 (MIFEPRISTONE): Mechanisms of Action and Clinical Uses

1997 • 413 citations

Cellular and molecular pharmacology of antiestrogen action and resistance.

2001 • 394 citations

Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer

1995 • 351 citations

Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells.

2003 • 325 citations

Characterization of the necrotic cleavage of poly(ADP-ribose) polymerase (PARP-1): implication of lysosomal proteases

2001 • 314 citations

Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression.

1993 • 295 citations

Estrogen-Dependent Cyclin E-cdk2 Activation through p21 Redistribution

1997 • 277 citations

Biological differences among MCF-7 human breast cancer cell lines from different laboratories

1987 • 267 citations

A Randomized Trial of Letrozole in Postmenopausal Women After Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer

2004 • 264 citations

Enhanced Epidermal Growth Factor Receptor Signaling in MCF7 Breast Cancer Cells after Long-Term Culture in the Presence of the Pure Antiestrogen ICI 182,780 (Faslodex)*

2001 • 253 citations

Caspase-8 Activation and Bid Cleavage Contribute to MCF7 Cellular Execution in a Caspase-3-dependent Manner during Staurosporine-mediated Apoptosis

2000 • 248 citations

Progesterone receptors - animal models and cell signaling in breast cancer: The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis

2002 • 245 citations

Update on estrogen signaling

2003 • 216 citations

MCF7/LCC2: a 4-hydroxytamoxifen resistant human breast cancer variant that retains sensitivity to the steroidal antiestrogen ICI 182,780.

1993 • 195 citations

Molecular Chaperone Interactions with Steroid Receptors: an Update

2000 • 193 citations

Intracellular signaling pathways: nongenomic actions of estrogens and ligand-independent activation of estrogen receptors

2001 • 178 citations

Steroid receptor-mediated cytotoxicity of an antiestrogen and an antiprogestin in breast cancer cells.

1987 • 172 citations

Estradiol Hypersensitivity and Mitogen-Activated Protein Kinase Expression in Long-Term Estrogen Deprived Human Breast Cancer Cellsin Vivo¹

2000 • 164 citations

?Studies on the estrogen receptor in breast cancer? ? 20 years as a target for the treatment and prevention of cancer

1995 • 155 citations

Cyclic Variation of DNA Synthesis in Human Breast Epithelium

1977 • 153 citations

Oestrogen receptor: a stable phenotype in breast cancer

1996 • 145 citations

Constitutive MEK/MAPK Activation Leads to p27Kip1Deregulation and Antiestrogen Resistance in Human Breast Cancer Cells

2001 • 141 citations

Various Phosphorylation Pathways, Depending on Agonist and Antagonist Binding to Endogenous Estrogen Receptor α (ERα), Differentially Affect ERα Extractability, Proteasome-Mediated Stability, and Transcriptional Activity in Human Breast Cancer Cells

2003 • 138 citations

Molecular and pharmacological aspects of antiestrogen resistance

2001 • 134 citations

Mechanisms of tamoxifen resistance

1994 • 123 citations

The evolution of tamoxifen therapy in breast cancer: selective oestrogen-receptor modulators and downregulators

2002 • 119 citations

Chemosensitivity testing of primary human renal cell carcinoma by a tetrazolium based microculture assay (MTT)

1990 • 117 citations

Caspase-9 processing by caspase-3 via a feedback amplification loop in vivo

2001 • 110 citations

Elevated mitogen-activated protein kinase activity in estrogen-nonresponsive human breast cancer cells.

1998 • 109 citations

Mechanisms of antihormone action

1992 • 104 citations

A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd

1984 • 96 citations

Tamoxifen resistant breast cancer: coregulators determine the direction of transcription by antagonist-occupied steroid receptors

1999 • 88 citations

The RB family of cell cycle regulatory factors

1998 • 81 citations

Clinical pharmacology of tamoxifen in patients with breast cancer: comparison of traditional and loading dose schedules.

1980 • 81 citations

Growth Factor, Steroid, and Steroid Antagonist Regulation of Cyclin Gene Expression Associated With Changes in T-47D Human Breast Cancer Cell Cycle Progression

1993 • 74 citations

Studies on the Estrogen Receptor in Breast Cancer

1973 • 72 citations

Estimation of Tamoxifen's Efficacy for Preventing the Formation and Growth of Breast Tumors

2000 • 68 citations

Molecular aspects of estrogen receptor variants in breast cancer

1995 • 65 citations

ICI 182,780 (Fulvestrant)--the first oestrogen receptor down-regulator--current clinical data.

2001 • 65 citations

Progestin Effects on Long-Term Growth, Death, and Bcl-xL in Breast Cancer Cells

2000 • 64 citations

Additive effect of mifepristone and tamoxifen on apoptotic pathways in MCF-7 human breast cancer cells

1998 • 63 citations

Progesterone receptors - animal models and cell signaling in breast cancer Diverse activation pathways for the progesterone receptor - possible implications for breast biology and cancer

2002 • 62 citations

Faslodex (ICI 182, 780), a novel estrogen receptor downregulator—future possibilities in breast cancer

2001 • 62 citations

Effect of antiprogestins and tamoxifen on growh inhibition of MCF-7 human breast cancer cells in nude mice

1998 • 49 citations

A mechanism of drug resistance to tamoxifen in breast cancer

2002 • 41 citations

Antitumor activity of mifepristone in the human LNCaP, LNCaP-C4, and LNCaP-C4-2 prostate cancer models in nude mice

2000 • 40 citations

Induction of antiproliferation and apoptosis in estrogen receptor negative MDA-231 human breast cancer cells by mifepristone and 4-hydroxytamoxifen combination therapy: A role for TGFβ1

2003 • 38 citations

Molecular action of the estrogen receptor and hormone dependency in breast cancer

2003 • 36 citations

Combined effects of RU486 and tamoxifen on the growth and cell cycle phases of the MCF-7 cell line.

1992 • 32 citations

Hormonal regulation of tumor suppressor proteins in breast cancer cells

2001 • 24 citations

Mifepristone pretreatment overcomes resistance of prostate cancer cells to tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL).

2002 • 23 citations

Resistance to Endocrine Therapy of Breast Cancer: Recent Advances and Tomorrow's Challenges

2001 • 20 citations

Mifepristone-induced secretion of transforming growth factor β1-induced apoptosis in prostate cancer cells

2002 • 18 citations

[Specific estrogen receptor modulators (SERMs)].

2002 • 13 citations

Arzoxifene in breast cancer

2002 • 11 citations

Intracellular signaling pathways nongenomic actions of estrogens and ligand-independent activation of estrogen receptors

2001 • 6 citations